Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens - PubMed (original) (raw)

. 2003 Dec 15;63(24):9007-15.

Affiliations

PMID: 14695219

Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens

Alex Cuenca et al. Cancer Res. 2003.

Abstract

A better understanding of how solid malignancies arise in an immunocompetent host, avoid immune recognition, and ultimately progress to widely disseminated cancer is essential to effectively harness the immune system against solid tumors. Because of their extra-lymphatic localization, it has been proposed that solid malignancies are just ignored by the immune system, thereby allowing their uncontrolled growth and dissemination. Alternatively, as most of the solid tumors are unable to express costimulatory molecules, the "signal one without signal two" model of tolerance induction has been frequently evoked to account for the failure of the immune system to reject antigenic tumors in vivo. In this study, we showed, however, that the extra-lymphatic growth of solid tumors is not immunologically ignored by the lymphoid compartment, resulting instead in the early induction of antigen-specific CD4(+) T-cell tolerance. Furthermore, analysis of parent-into-F1 bone marrow (BM) chimeras demonstrates that presentation of tumor antigens by BM-derived antigen-presenting cells represents the dominant mechanism in solid tumor-induced CD4(+) T-cell tolerance. Our findings of early development of antigen-specific T-cell unresponsiveness mediated by BM-derived antigen-presenting cells, not only provides a plausible explanation for the failure of the immune system to reject antigenic solid tumors in vivo, but more importantly, they have identified a barrier that, if appropriately manipulated, may lead to approaches to effectively harness the immune system against solid malignancies.

PubMed Disclaimer

Cited by

Clinical uses of GM-CSF, a critical appraisal and update.
Arellano M, Lonial S. Arellano M, et al. Biologics. 2008 Mar;2(1):13-27. doi: 10.2147/btt.s1355. Biologics. 2008. PMID: 19707424 Free PMC article.
Tumor antigen analysis in neuroblastoma by serological interrogation of bioinformatic data.
Kohler ME, Johnson BD, Palen K, Chen QR, Khan J, Orentas RJ. Kohler ME, et al. Cancer Sci. 2010 Nov;101(11):2316-24. doi: 10.1111/j.1349-7006.2010.01694.x. Cancer Sci. 2010. PMID: 20718755 Free PMC article.
Cross-priming in health and disease.
Kurts C, Robinson BW, Knolle PA. Kurts C, et al. Nat Rev Immunol. 2010 Jun;10(6):403-14. doi: 10.1038/nri2780. Nat Rev Immunol. 2010. PMID: 20498667 Review.
Nasal Tumor Vaccination Protects against Lung Tumor Development by Induction of Resident Effector and Memory Anti-Tumor Immune Responses.
Donkor M, Choe J, Reid DM, Quinn B, Pulse M, Ranjan A, Chaudhary P, Jones HP. Donkor M, et al. Pharmaceutics. 2023 Jan 29;15(2):445. doi: 10.3390/pharmaceutics15020445. Pharmaceutics. 2023. PMID: 36839766 Free PMC article.
How numbers, nature, and immune status of foxp3(+) regulatory T-cells shape the early immunological events in tumor development.
Darrasse-Jèze G, Podsypanina K. Darrasse-Jèze G, et al. Front Immunol. 2013 Sep 26;4:292. doi: 10.3389/fimmu.2013.00292. Front Immunol. 2013. PMID: 24133490 Free PMC article. Review.

Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens - PubMed (original) (raw)